AstraZeneca, the largest pharmaceutical company in the United Kingdom, plans to invest £300 million ($405 million) in the UK life sciences sector. Prime Minister Keir Starmer announced this significant investment in parliament, highlighting its potential to safeguard 1,000 jobs in Macclesfield and Cambridge. This decision comes after AstraZeneca had previously halted major projects, including a £200 million investment in Cambridge and a scrapped £450 million vaccine manufacturing plant in northern England, citing an unfavorable business environment and reduced government support. The new investment is facilitated by a pharmaceutical arrangement with the United States, which aims to align UK medicine prices with U.S. policies. AstraZeneca and other drugmakers have expressed concerns that Europe may miss out on new medicines due to the changing policy landscape.